TY  - CHAP
M1  - Book, Section
TI  - The Chronic Myelogenous Leukemias
A1  - Lichtman, Marshall A.
A1  - Kaushansky, Kenneth
A1  - Prchal, Josef T.
A1  - Levi, Marcel M.
A1  - Burns, Linda J.
A1  - Armitage, James O.
Y1  - 2017
N1  - 
T2  - Williams Manual of Hematology, 9e
AB  - BCR-ABL1–positive  chronic  myelogenous  leukemia  (CML)  results  from  a  somatic  mutation  in  a  pluripotential  lymphohematopoietic  cell,  yielding  a  fusion  oncogene  (BCR-ABL1).CML  is  characterized  by  granulocytic  leukocytosis,  granulocytic  immaturity,  basophilia,  anemia,  and  often  thrombocytosis  in  the  blood,  intense  leukemic  granulocytic  precursor  expansion  in  the  marrow,  and  splenomegaly.The  natural  history  of  the  disease  is  to  evolve  into  an  accelerated  phase  in  which  cytopenias  develop  and  response  to  chronic  phase  therapy  is  lost;  either  the  chronic  or  accelerated  phase  can  undergo  further  clonal  evolution  to  acute  leukemia.This  natural  history  has  been  modified  significantly  by  the  introduction  of  inhibitors  of  the  constitutive  kinase  activity  of  the  BCR-ABL1  oncoprotein.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - hemonc.mhmedical.com/content.aspx?aid=1133364237
ER  -